Article Text

other Versions

PDF
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double masked open label clinical trial
  1. Mohsen Bahmani Kashkouli1,
  2. Ali Jalili Fazel1,
  3. Victoria Kiavash1,
  4. Marzieh Nojomi2,
  5. Leila Ghiasian3
  1. 1Eye Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2Epidemiology and Community Medicine Department, Iran University of Medical Sciences, Tehran, Iran
  3. 3Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  1. Correspondence to Dr Mohsen Bahmani Kashkouli, Eye Research Center, Rassoul Akram Hospital, Sattarkhan-Niayesh St, Tehran 14455-364, Iran; bahmanik{at}yahoo.com

Abstract

Background/aims To assess the efficacy and safety of oral azithromycin compared with oral doxycycline in patients with meibomian gland dysfunction (MGD) who had failed to respond to prior conservative management.

Methods 110 patients (>12 years old) with MGD were randomly assigned to receive either oral 5-day azithromycin (500 mg on day 1 and then 250 mg/day) or 1-month doxycycline (200 mg/day). They also continued eyelid warming/cleaning and artificial tears. A score comprising five symptoms and seven signs (primary outcome) was recorded prior to treatment and at 1 week, and 1 and 2 months after treatment. Total score was the sum of both scores at each follow-up. Side effects were recorded and overall clinical improvement was categorised as excellent, good, fair or poor based on the percentage of change in the total score.

Results Symptoms and signs improved significantly in both groups (p=0.001). While improvement of symptoms was not different between the groups, bulbar conjunctival redness (p=0.004) and ocular surface staining (p=0.01) were significantly better in the azithromycin group. The azithromycin group showed a significantly better overall clinical response (p=0.01). Mild gastrointestinal side effects were not significantly different between the groups except for the second visit, when the doxycycline group had significantly more side effects (p=0.002).

Conclusions Although both oral azithromycin and doxycycline improved the symptoms of MGD, 5-day oral azithromycin is recommended for its better effect on improving the signs, better overall clinical response and shorter duration of treatment.

Trial registration number NCT01783860.

  • Ocular Surface
  • Treatment Medical
  • Eye Lids
  • Inflammation
  • Microbiology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas